Mizuho Boosts PT on Clovis Oncology (CLVS) to $23 Following Rucaparib NDA Approval
Tweet Send to a Friend
Mizuho boosts its price taget on Neutral-rated Clovis Oncology (Nasdaq: CLVS) from $15 to $23 after the company announced that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
